MX348735B - Celulas madre mesenquimales que expresan los receptores tnf-alfa. - Google Patents

Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Info

Publication number
MX348735B
MX348735B MX2013002845A MX2013002845A MX348735B MX 348735 B MX348735 B MX 348735B MX 2013002845 A MX2013002845 A MX 2013002845A MX 2013002845 A MX2013002845 A MX 2013002845A MX 348735 B MX348735 B MX 348735B
Authority
MX
Mexico
Prior art keywords
stem cells
mesenchymal stem
receptor
cells expressing
expressing tnf
Prior art date
Application number
MX2013002845A
Other languages
English (en)
Inventor
Danilkovitch Alla
Carter Diane
Tyrell Alicia
Bubnic Simon
Marcelino Michelle
Monroy Rodney
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of MX348735B publication Critical patent/MX348735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Abstract

La presente invención se refiere a una composición que comprende una población de células madre mesenquimales que han sido criopreservadas a una temperatura de al menos -70°C o menos y descongeladas, la cual caracterizada porque comprende una población terapéuticamente efectiva de células madre mesenquimales; en donde la población terapéuticamente efectiva de células madre mesenquimales expresan receptor de TNF-a Tipo I en una cantidad de al menos 13 pg/106 células; y una solución de criopreservación; y en donde las células madre mesenquimales son no transfectadas y suprimen proliferación mononuclear de sangre periférica humana (Hpbmc).
MX2013002845A 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa. MX348735B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75915706P 2006-01-13 2006-01-13
PCT/US2007/000274 WO2007087139A2 (en) 2006-01-13 2007-01-05 MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR

Publications (1)

Publication Number Publication Date
MX348735B true MX348735B (es) 2017-06-27

Family

ID=38309740

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013002845A MX348735B (es) 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa.
MX2008008774A MX2008008774A (es) 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2008008774A MX2008008774A (es) 2006-01-13 2007-01-05 Celulas madre mesenquimales que expresan los receptores tnf-alfa.

Country Status (11)

Country Link
US (9) US20070258963A1 (es)
EP (3) EP1971679B1 (es)
CN (1) CN101370930A (es)
AU (1) AU2007208504B2 (es)
BR (1) BRPI0706529A2 (es)
CA (2) CA2893204C (es)
ES (1) ES2415855T3 (es)
HK (1) HK1151553A1 (es)
MX (2) MX348735B (es)
WO (1) WO2007087139A2 (es)
ZA (1) ZA200805609B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032401A1 (en) 2005-12-29 2008-02-07 James Edinger Placental stem cell populations
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1971679B1 (en) * 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
NZ601497A (en) 2008-08-20 2014-03-28 Anthrogenesis Corp Improved cell composition and methods of making the same
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2367932B1 (en) 2008-11-19 2019-06-12 Celularity, Inc. Amnion derived adherent cells
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
EP3130667B1 (en) * 2009-11-27 2021-08-04 Stempeutics Research PVT. Ltd. Methods of preparing mesenchymal stem cells, compositions and kit thereof
AU2011237743A1 (en) 2010-04-08 2012-11-01 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
PL2620156T3 (pl) * 2010-08-23 2019-10-31 Kang Stem Biotech Co Ltd Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób immunologicznych lub chorób zapalnych, zawierająca komórki macierzyste traktowane agonistą NOD2 lub jego produktem hodowlanym
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells
ES2675693T3 (es) 2011-07-06 2018-07-11 Cell Therapy Limited Células progenitoras de linaje mesodérmico
KR102312720B1 (ko) 2013-03-15 2021-10-13 알로소스 연조직 회복 및 재생을 위한 세포 재배치된 콜라겐 매트릭스
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CA3062112A1 (en) 2017-05-04 2018-11-08 Mesoblast International Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
US11701391B2 (en) 2017-10-24 2023-07-18 Dalia ELANI Methods of treating an ischemic disease
CN110938668A (zh) * 2019-11-21 2020-03-31 北京贝来生物科技有限公司 一种间充质干细胞生物学效力的检测方法
KR20230047136A (ko) * 2020-08-10 2023-04-06 메조블라스트 인터내셔널 에스에이알엘 중간엽 전구세포 또는 줄기세포를 포함하는 조성물 및 이의 용도
WO2024009226A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl Cryopreserved intermediate and potency assay for same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
AU2701895A (en) 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5955257A (en) * 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU755888B2 (en) * 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1066060B1 (en) 1998-04-03 2003-08-13 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6225119B1 (en) 1998-05-22 2001-05-01 Osiris Therapeutics, Inc. Production of megakaryocytes by the use of human mesenchymal stem cells
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU7611500A (en) * 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7144729B2 (en) * 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
ITTO20020311A1 (it) 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
US20060134596A1 (en) * 2003-05-08 2006-06-22 Anita Sjogren Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20060063141A1 (en) * 2004-09-17 2006-03-23 Mcgann Locksley E Method of cryopreserving cells
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
EP1971679B1 (en) 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
KR100908481B1 (ko) 2006-04-24 2009-07-21 코아스템(주) 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법
NZ602248A (en) 2008-08-14 2014-03-28 Osiris Therapeutics Inc Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
JP7315301B2 (ja) 2014-12-23 2023-07-26 メゾブラスト・インターナショナル・エスアーエールエル 進行性心不全の予防
CA3084575A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
SG11202106794WA (en) 2019-01-02 2021-07-29 Mesoblast Int Sarl Method for treating lower back pain
BR112021012923A2 (pt) 2019-01-03 2021-09-14 Mesoblast International Sàrl Método para melhorar a acuidade visual
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
CN113853206A (zh) 2019-05-23 2021-12-28 迈索布拉斯特国际有限公司 脑梗塞的功能恢复
WO2021024207A1 (en) 2019-08-05 2021-02-11 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
US20230097931A1 (en) 2020-02-19 2023-03-30 Mesoblast International Sárl Method for treating chronic graft versus host disease
BR112022018022A2 (pt) 2020-03-11 2022-10-18 Mesoblast Int Sarl Método para tratar doença inflamatória intestinal ii

Also Published As

Publication number Publication date
CN101370930A (zh) 2009-02-18
HK1151553A1 (en) 2012-02-03
EP2465922A2 (en) 2012-06-20
EP1971679B1 (en) 2013-04-10
US20070258963A1 (en) 2007-11-08
CA2893204A1 (en) 2007-08-02
US20140248244A1 (en) 2014-09-04
MX2008008774A (es) 2008-09-26
EP2465922B1 (en) 2018-08-01
BRPI0706529A2 (pt) 2011-03-29
US20210171913A1 (en) 2021-06-10
US20120214178A1 (en) 2012-08-23
EP3287520A1 (en) 2018-02-28
US20130259841A1 (en) 2013-10-03
EP1971679A2 (en) 2008-09-24
US20090169522A1 (en) 2009-07-02
AU2007208504A1 (en) 2007-08-02
ES2415855T3 (es) 2013-07-29
US8486695B2 (en) 2013-07-16
WO2007087139A2 (en) 2007-08-02
CA2635915A1 (en) 2007-08-02
AU2007208504B2 (en) 2011-04-21
US20150004693A1 (en) 2015-01-01
US11821004B2 (en) 2023-11-21
CA2635915C (en) 2015-09-08
WO2007087139A3 (en) 2007-10-11
EP2465922A3 (en) 2012-12-05
ZA200805609B (en) 2009-04-29
US20180087032A1 (en) 2018-03-29
US20110189768A1 (en) 2011-08-04
EP1971679A4 (en) 2009-12-09
CA2893204C (en) 2016-11-29

Similar Documents

Publication Publication Date Title
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
RS20080336A (en) Activin-actriia antagonists and uses for promoting bone growth
MX2010008696A (es) Composiciones de proteina estabilizadas.
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MY159971A (en) Multipotent/pluripotent cells and methods
MX2009006651A (es) Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2005117557A3 (en) Expression system
WO2009135905A3 (en) Mesenchymal stem cells and bone-forming cells
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
TW200611910A (en) Interferon-alpha polypeptides and conjugates
ATE553792T1 (de) Medizinische vorrichtungen mit verbundstoffen
WO2008060788A3 (en) Compositions, methods, and devices for treating liver disease
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
ZA200704260B (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
SG158133A1 (en) Method for reversing multiple resistance in animal cells
EP1841781A4 (en) USE OF IL-22 FOR THE TREATMENT OF METABOLISM DISORDER
WO2009149359A3 (en) Survival predictor for diffuse large b cell lymphoma
AU2010207073A8 (en) Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
MX2009009822A (es) Composiciones y metodos para reducir niveles de h2s en bebidas fermentadas.
AU316238S (en) Lawning applicator for microbiological cultures
UA98447C2 (ru) АНТАГОНИСТЫ АКТИВИНА- ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ СОДЕЙСТВИЯ РОСТУ КОСТЕЙ